Breakthrough infections with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-
2) in fully vaccinated individuals are receiving intense scrutiny because of their importance …

Where 2020 saw the development and testing of vaccines against severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) at an unprecedented pace, the first half of 2021 has …

The severe acute respiratory distress syndrome coronavirus 2 (SARS-CoV-2) Omicron
variant is spreading rapidly, even in vaccinated individuals, raising concerns about immune …

Background Vaccine effectiveness against COVID-19 beyond 6 months remains
incompletely understood. We aimed to investigate the effectiveness of COVID-19 …

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant of
concern comprises several sublineages, with BA. 2 and BA. 2.12. 1 having replaced the …

A large body of evidence generated in the last two and a half years addresses the roles of T
cells in SARS-CoV-2 infection and following vaccination. Infection or vaccination induces …

Background Vaccines are critical cost-effective tools to control the coronavirus disease 2019
(COVID-19) pandemic. However, the emergence of variants of the severe acute respiratory …

Background The safety and efficacy of the AZD1222 (ChAdOx1 nCoV-19) vaccine in a large,
diverse population at increased risk for severe acute respiratory syndrome coronavirus 2 …

With the relatively rapid development of the COVID-19 pandemic, vaccine development has
become crucial for limiting disease transmission. The accelerated growth in the approved …

The global supply of COVID-19 vaccines remains limited. An understanding of the immune
response that is predictive of protection could facilitate rapid licensure of new vaccines. Data …